Is mirtazapine appropriate for treating restless legs syndrome, and what is the recommended dosing and monitoring strategy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mirtazapine Should NOT Be Used for Restless Legs Syndrome

Mirtazapine is contraindicated for treating restless legs syndrome (RLS) and may actually cause or worsen RLS symptoms. The most recent 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline does not include mirtazapine as a treatment option for RLS, and research evidence consistently demonstrates that mirtazapine is among the antidepressants most likely to provoke or exacerbate RLS 1.

Why Mirtazapine is Inappropriate for RLS

Evidence of Harm

  • Mirtazapine has the highest rate of RLS induction among antidepressants, causing or worsening RLS in 28% of patients 2
  • RLS symptoms typically develop within the first few days of starting mirtazapine 3, 2
  • Multiple case reports document mirtazapine-induced RLS that resolves upon discontinuation 4, 5

Risk Factors for Mirtazapine-Associated RLS

If a patient is already on mirtazapine and develops RLS, certain concomitant medications significantly increase risk:

  • Tramadol (odds ratio: 8.61) 3
  • Dopamine-blocking agents (odds ratio: 4.67) 3
  • Non-opioid analgesics and antihistamines also increase risk 3

Recommended Treatment Approach for RLS

Based on the 2025 AASM guidelines, the appropriate treatment hierarchy is 1:

First-Line Treatments (Strong Recommendations)

  1. Gabapentin enacarbil - preferred for symptoms throughout the day
  2. Gabapentin - standard formulation
  3. Pregabalin - alternative α-2-δ ligand
  4. IV ferric carboxymaltose - if ferritin <75 ng/mL or transferrin saturation <20%

Second-Line Options (Conditional Recommendations)

  • Ferrous sulfate (oral iron) - for appropriate iron status
  • Extended-release oxycodone or other opioids - for refractory cases
  • Dipyridamole - alternative option

Medications to AVOID (Conditional to Strong Recommendations Against)

  • Dopamine agonists (pramipexole, ropinirole, rotigotine) - risk of augmentation with long-term use 1
  • Bupropion - suggested against 1
  • Cabergoline - strong recommendation against 1
  • Benzodiazepines (clonazepam) - suggested against 1

Clinical Pitfalls

Common mistake: Using mirtazapine in patients with comorbid depression and RLS. While depression frequently coexists with RLS, mirtazapine will likely worsen the RLS symptoms 6, 7.

Better alternative for comorbid depression: If antidepressant therapy is needed in RLS patients, consider:

  • Bupropion - may actually reduce RLS symptoms short-term 1, 6
  • Agomelatine - has sleep-promoting properties without worsening RLS 7
  • Reboxetine - no cases of RLS reported 2

Monitoring Strategy

If a patient develops RLS while on mirtazapine:

  1. Discontinue mirtazapine - symptoms typically resolve upon cessation 4, 5
  2. Taper gradually per FDA labeling to avoid discontinuation syndrome 8
  3. Switch to RLS-appropriate therapy from the first-line options above
  4. Check iron studies - ferritin and transferrin saturation before initiating treatment

The evidence is unequivocal: mirtazapine is not a treatment for RLS and represents a potential cause of the condition. Treatment should focus on the evidence-based options outlined in the 2025 AASM guidelines, with gabapentinoids and iron supplementation as first-line approaches.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.